The large-scale biologics manufacturing plant of Genentech in Vacaville will be purchased by Lonza from the parent company of Genentech for $1.2 billion.
The goal of this acquisition will be to increase the capacity of Lonza for manufacturing biologics at commercial scale. News of such acquisitions is often made known throughout an industry with flyer printing.
The plant in Vacaville is one of the largest sites for biologics manufacturing in the world. Lonza said it plans to increase the capacity of the plant in the coming year with an investment of $556.6 million in next-generation mammalian biologics therapies to upgrade the facility. This is a project that will enable the company to meet the demand for therapies for next-generation mammalian biologics from customers with existing commercial products as well as from those with therapies that are currently being developed into commercial products.
The plant in Vacaville will create a significant presence on the west cost of the United States for the company in commercial manufacturing, which will complement the existing biologics site on the east coast in Portsmouth, New Hampshire. The president of Lonza, Jean-Christophe Hyvert, added that the site in Vacaville is a strategic acquisition for the company that will create growth in the future for the company’s biologics division.
Lonza said that employment will be offered to the 750 Genentech employees currently working at the plant.
